• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Arthritis Center

Show Search
Hide Search
  • Disease Information
    • Rheumatoid Arthritis
    • Psoriatic Arthritis
    • Ankylosing Spondylitis
    • Osteoarthritis
    • Gout
    • Osteoporosis
  • Patient Corner
    • Drug Information Sheets
    • Managing Your Arthritis
    • RheumTV – Patient Education Video Library
  • Our Research
    • Patient-Centered Outcomes Research
    • Current Research Studies
    • The Camille Julia Morgan Arthritis Research and Education Fund
  • About Us
    • Appointment Information
    • Contact Us
    • Our Faculty
    • Our Staff
    • Rheumatology Specialty Centers
  • Donate
Home / Arthritis News / PAD-4 Autoantibodies Identified as a Novel Severity Factor in RA

PAD-4 Autoantibodies Identified as a Novel Severity Factor in RA

September 30, 2008 By Arthritis Center

Rheumatoid Arthritis

Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease.  The enzymes that catalyze the citrullination process, known as peptidyl argenine deiminases (or PADs), may also be involved in the initiation and propagation steps of the RA disease process.  Additionally, autoimmunity to these catalysts may identify a subset of RA patients with unique disease phenotypes.  Here, Harris et al (Arthritis Rheum 2008;58:1958) investigate the associations of antibodies against PAD4 with the genotypic and phenotypic features of RA.

Methods and Results

Anti-PAD4 antibodies in RA

Antibodies against PAD4 were detected in 16 out of 38 RA patients (42%), but in none of 32 healthy controls and in only 1 of 126 patients (0.8%) with other rheumatic diseases (scleroderma, myositis, lupus, and primary Sjogren’s)—yielding a sensitivity of 42% and specificity of 99% for RA.  Clinical characteristics of PAD4 antibody positive patients were similar to those of negative patients with the exception of disease duration, which was significantly higher in PAD4 antibody positive patients.

Targeting of PAD4 epitopes by anti-PAD4 antibodies

All PAD4 antibody positive RA sera recognized full length PAD4 (designated as type I sera) while only 48% of sera recognized a truncated form of the PAD4 protein.  Further investigation demonstrated that PAD4 lacking the first 119 amino acids of the N terminus was not recognized by either Type I or Type II sera, indicating the necessity of these amino acids for antibody recognition.  Additional studies demonstrated that Type I sera also required the 141 C terminal amino acids in addition to the N terminal amino acids in order to recognize PAD4.  The crystal structure of PAD4 includes head-to-tail contact between the N and C terminus of PAD4.  Polymorphisms in the PADI4 gene encoding PAD4 did not alter recognition of PAD4 by PAD4 antibody positive sera.

Association of anti-PAD4 antibodies with susceptibility haplotype of PADI4

Previous studies have established 3 SNP polymorphisms within the PADI4 gene associated with an increased susceptibility for RA that also happen to encode amino acids in the N-terminal region recognized by PAD4 antibodies.  Heterozygosity for one of these PADI4 susceptibility haplotypes was associated with a significantly higher odds of having PAD4 antibodies (OR 2.59 (95%CI 1.02-6.08)).

Association of anti-PAD4 antibodies with radiographic damage

RA patients with 3+ PAD4 antibody expression had higher mean total Sharp scores compared to those with no PAD4 antibodies (57 vs. 132 units; p < 0.001).  The difference remained significant after adjusting for age, RA duration, swollen joint count, RF, HLA-DRB1 shared epitope alleles, and current use of biologic and non-biologic DMARDs

Anti-PAD4 antibodies and anti-CCP antibody status

The presence of anti-CCP antibodies was highly associated with the presence of anti-PAD4 antibodies (OR 6.17 (95%CI 1.88-16.6)).  Anti-CCP antibodies were also highly associated with HLA-DRB1 shared epitope alleles.  However, anti-PAD4 antibodies were not associated with shared epitope alleles—suggesting a mechanism independent of both anti-CCP and shared epitope.

Conclusions

Anti-PAD4 antibodies were highly specific for RA and all recognized a portion of the PAD4 enzyme protein containing regions encoded by variants in the PADI4 gene known to increase the risk of RA.  Presence of anti-PAD4 antibodies was associated with longer disease duration and more severe radiographic damage.

Editorial Comment

This report introduces a novel RA factor that may link the process of citrullination to the initiation and propagation steps of the RA disease process.  The association of PAD4 antibodies with longer standing disease suggests that these antibodies may occur after the initiating steps of disease and may represent a later risk factor for radiographic damage.  The exact mechanism and dynamics leading to damage by anti-PAD4 antibodies are unclear.  However, if implicated directly in radiographic damage, then suppression of their development (perhaps with early aggressive therapy) might be a way to limit accumulated radiographic damage over time.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

Use of this Site

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Recent News

Exercise Tips for Arthritis Patients

How Does Exercise Affect my Joints? How Frequently Should I Be Exercising? Should I Lose Weight for Exercise to be

Risks and Benefits of Biologic Medications

Victoria Ruffing, RN, BC, Director of Patient Education at the Johns Hopkins Arthritis Center, shares the risks and benefits of biologic for

How to Manage Rheumatoid Arthritis Flares

Through research, doctors have a clearer understanding of how flares can impact a patient on a personal and emotional level. Dr. Uzma Haque

Complementary & Alternative Medicines for Psoriatic Arthritis

There are many complementary & alternative medicines and practices that have been found to be beneficial in curbing arthritis pain,

I can’t be a runner because I have Rheumatoid Arthritis (RA), right?

Dr. Manno discusses running and Rheumatoid Arthritis. Is it an option for the RA patient?

News Categories

  • Ankylosing Spondylitis News
  • Fibromyalgia News
  • Gout News
  • Lupus News
  • Osteoarthritis News
  • Osteoporosis News
  • Psoriatic Arthritis News
  • Rheumatoid Arthritis News
RheumTV Logo

Rheum.TV is an informational platform created to educate patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit Rheum.TV

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube

Johns Hopkins Medicine

© 2023 Johns Hopkins Arthritis Center
Patient Privacy